PDCD1 and melanoma: Preliminary data from a clinical trial of LAG-3 antibody (liratrimab) in combination with nivolumab in melanoma patients suggested that it was more effective than nivolumab alone, suggesting that the anti-LAG-3 antibody may have clinical efficacy as a third ICI pathway following PD-1 and CTLA-4 [143].